PTPN2 and neoplasm: Tamoxifen treatment was associated with a strongly reduced risk of distant recurrence in the group of patients with ER-positive tumour and high PTPN2 concurrent with low pAkt expression, whereas no significant benefit from tamoxifen could be seen in the group with low PTPN2 and/or high nuclear pAkt (interaction test P = 0.044, Table 2; Fig. 4a, b).